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EditorialCorticosteroids can be used to treat alcoholic hepatitis
after a recent upper gastrointestinal bleed
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See Article, pages 816–821Alcoholic hepatitis (AH) is a disease that is diagnosed clinically by
a constellation of ﬁndings, including a long and recent history of
heavy alcohol use, onset of jaundice within the prior 3 months,
and AST>ALT (and AST usually <500 IU/ml). Patients with severe
AH usually have ascites and are malnourished, and not uncom-
monly have hepatic encephalopathy. Other causes of liver disease
need to be excluded based on blood tests (e.g., autoimmune hep-
atitis) or tested for (e.g., hepatitis C, hepatitis B). Imaging of the
abdomen and liver is recommended to evaluate for ascites,
masses in the liver, biliary duct obstruction, and vascular struc-
tures. Infections in the urine, ascites, blood and, if indicated, lungs
should be routinely assessed. Liver biopsy is helpful to make the
diagnosis of AH and to differentiate from alcoholic cirrhosis with-
out features of AH. However, in practice, most clinicians do not
perform liver biopsy. Studies in which patients with clinical AH
were biopsied found that most patients with histologic AH have
underlying alcoholic cirrhosis [1].
EASL and AASLD guidelines recommend patients with AH and
a Maddrey’s Discriminant Function score (DF) >32 receive pred-
nisolone 40 mg/day for 4 weeks [2,3]. However, both EASL and
AASLD guidelines specify that patients with recent upper gastro-
intestinal (UGI) bleed or with renal failure are not ideal candi-
dates for prednisolone treatment. The reason for excluding
patients with recent UGI bleeding is a carryover from clinical tri-
als performed in the 1970’s and 1980’s in which patients with
UGI bleeding were excluded. Although the justiﬁcation for
excluding patients with recent UGI bleeding from older studies
is speculative, I believe there were two major reasons. First, there
was widespread belief in the 1970s and 1980s that corticoste-
roids caused duodenal ulcers. Second, there was no effective
treatment for UGI bleeding. Many cirrhotic patients with UGI
bleeding died from repeat bleeding (or its complications: infec-
tion and renal failure) within a week or two, thereby limiting
the efﬁcacy of a drug that required several weeks to provide
efﬁcacy.
Muchhas changed in thepast 30–40 years. First, corticosteroids
mildly increase the risk of UGI bleeding, especially in patientswith
liver disease [4]. If one is concerned about corticosteroids causingJournal of Hepatology 20
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Open access under CC BY-NC-ND license.ulcers one can add an H2 blocker or proton pump inhibitor
(although there is reason to avoid proton pump inhibitors in
patients with advanced cirrhosis [5]). Second, we now have treat-
ments for most causes of UGI bleeding in AH. Endoscopic variceal
band ligationplusbeta blockers reduce esophageal variceal reblee-
ding risk andmay improve survival [6,7]. Various endoscopic tech-
niques, including injection and clips, can be used to reduce
rebleeding from bleeding non-variceal sources in the stomach
and duodenum [8]. Transjugular intrahepatic portosystemic
shunts can reduceUGI bleeding in cirrhotic patientswho fail endo-
scopic methods [9]. Finally, antibiotics, given for 7 days after gas-
trointestinal bleeding in a cirrhotic patient, reduce infections and
increase survival [10]. Taken together, these treatments reduce
the likelihood that a cirrhotic patient with UGI bleeding will die
in the short-term. Thus, it seems reasonable to ask whether recent
UGI bleeding should remain an exclusion to prednisolone treat-
ment in AH.
Rudler and colleagues from Hôpital Pitié-Salpêtrière in Paris
have conducted a retrospective analysis of survival among
patients with biopsy-proven AH who presented to hospital
between 2005 and 2011 with recent UGI bleed as compared with
patients with AH who were admitted without UGI bleeding [11].
A total of 58 patients with UGI bleed and 47 patients without UGI
bleed were analyzed. The two groups did not differ in presence of
AH on biopsy (approximately 80%), DF or MELD score. 6-month
survival was similar in both groups (74% vs. 70%). The probability
of developing an infection after starting steroids was lower
among subjects with UGI bleed (24%) as compared with subjects
without an UGI bleed (45%).
How do we incorporate these data into our current thinking
about treatment of AH? Although this is a retrospective study, I
believe the data are sufﬁciently strong that we should not
exclude patients with AH and recent UGI bleeding from receiving
prednisolone treatment. My reasoning is largely based on data,
cited above, that UGI bleeding is no longer a major deterrent
for short-term survival (especially if one waits 48 h or longer
after the acute bleeding before starting corticosteroids) and that
prednisolone minimally increases UGI bleeding risk.
The reduction in infections among subjects with UGI bleeding
is provocative. The authors speculate that prophylactic antibiot-
ics, routinely given for 7 days after an UGI bleed, reduced the risk
of infection. This explanation seems plausible. However, despite15 vol. 62 j 759–760
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the reduction in infections, 1-month and 6-month survival was
similar in the GIB and the non-GIB groups. The reason for the lack
of reduction in mortality is not directly addressed by the authors.
In my opinion, the data are not sufﬁciently strong to suggest that
antibiotics be routinely prescribed to patients with AH to prevent
infections.
The position that prednisolone can be safely administered to
subjects with recent UGI bleeding would be strengthened if other
investigators would retrospectively analyze their database of AH,
either individually, or collective (as a type of meta-analysis of
primary data) for survival according to recent UGI bleeding. I don’t
believe there will ever be a randomized control trial of predniso-
lone treatment (vs. no treatment) among AH patients with recent
UGI bleeding. Until additional data are available, I will aggressively
manage UGI bleeding in AH endoscopically, administer antibiotics
for 7 days, and, if the patient has not re-bled for 48 h or longer, rec-
ommend prednisolone 40 mg/day for 28 days.Conﬂict of interest
The author declared that he does not have anything to disclose
regarding funding or conﬂict of interest with respect to this
manuscript.
The underlying research reported in the study was funded by
the NIH Institutes of Health.
Acknowledgements
This manuscript was supported in part by the National Institute
on Alcohol Abuse and Alcoholism of the National Institutes of
Health under award number U01AA021886.760 Journal of Hepatology 201References
[1] Hardy T et al. White cell count and platelet count associate with histological
alcoholic hepatitis in jaundiced harmful drinkers. BMC Gastroenterol
2013;13:55.
[2] European Association for the Study of L. EASL clinical practical guidelines:
management of alcoholic liver disease. J Hepatol 2012;57:399–420.
[3] O’Shea RS et al. Alcoholic liver disease. Hepatology 2010;51:307–328.
[4] Narum S, Westergren T, Klemp M. Corticosteroids and risk of gastrointestinal
bleeding: a systematic review and meta-analysis. BMJ Open 2014;4:
e004587.
[5] O’Leary JG et al. Long-term use of antibiotics and proton pump inhibitors
predict development of infections in patients with cirrhosis. Clin Gastroen-
terol Hepatol 2014. http://dx.doi.org/10.1016/j.cgh.2014.07.060, [Epub
ahead of print].
[6] O’Brien J, Triantos C, Burroughs AK. Management of varices in patients with
cirrhosis. Nat Rev Gastroenterol Hepatol 2013;10:402–412.
[7] Garcia-Tsao G, Bosch J. Management of varices and variceal hemorrhage in
cirrhosis. N Engl J Med 2010;362:823–832.
[8] Laine L, Jensen DM. Management of patients with ulcer bleeding. Am J
Gastroenterol 2012;107(3):345–360, quiz 361.
[9] Garcia-Pagan JC et al. Early use of TIPS in patients with cirrhosis and variceal
bleeding. N Engl J Med 2010;362:2370–2379.
[10] Chavez-Tapia NC et al. Antibiotic prophylaxis for cirrhotic patients with
upper gastrointestinal bleeding. Cochrane Database Syst Rev 2010;9:
CD002907.
[11] Rudler M, Mouri S, Charlotte F, Lebray P, Capocci R, Benosman H, et al.
Prognosis of treated severe alcoholic hepatitis in patients with gastro-
intestinal bleeding. J Hepatol 2015;62:816–821.5 vol. 62 j 759–760
